Filing identity and business context
Important: The supplied filing is Chavant Capital Acquisition Corp.’s Form 10-Q for the quarter ended June 30, 2022; it is not a Mobix Labs, Inc. filing. The company describes itself as a shell company formed to pursue a business combination. It had no operating business or revenue as of the reporting date.
Financial results and liquidity
- Revenue: No operating revenue in the three or six months ended June 30, 2022.
- Net income: $34,785 for the quarter, versus a $46,205 loss in the 2021 quarter; $639,144 for the six months, versus a $47,987 loss in the comparable 2021 period. 2022 earnings primarily reflected noncash gains from warrant remeasurement: $425,000 for the quarter and $1,412,262 for the six months. Operating expenses were $426,465 and $811,341, respectively.
- Cash flow: Six-month operating cash outflow was $259,138; financing provided $150,000. Cash declined $109,138 to $131,568.
- Assets and liabilities: At June 30, cash was $131,568, prepaid expenses $43,454, and trust investments $80,041,000. Total liabilities were $637,068, including a $255,000 warrant liability and $150,000 due to the sponsor. Redeemable shares of $80 million were classified as temporary equity, not conventional debt.
- Liquidity: The company reported a $462,046 working capital deficiency and stated that outside-trust cash was insufficient to fund operations for the next 12 months absent a business combination. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
Material changes and subsequent events
On July 14, 2022, shareholders approved extending the business-combination deadline from July 22, 2022 to January 22, 2023. In connection with the extension, 7,046,967 shares were redeemed for $70,573,278 from the trust. As of August 16, 2022, 2,953,033 ordinary shares were outstanding. The filing does not give a clear post-redemption trust balance.
By August 16, the company reported $172,000 drawn under sponsor working-capital loans. The filing also describes sponsor notes issued for larger amounts; the relationship between those note amounts and amounts drawn should be checked.
Outlook, risks, and unusual items
- Management intended to complete a business combination by the extended deadline, but gave no operating or financial forecast and offered no assurance of completion.
- If no combination is completed by January 22, 2023, public shares are to be redeemed from the trust, subject to stated terms; warrants may expire worthless.
- Key risks include limited outside-trust liquidity, dependence on sponsor financing, potential creditor claims against trust assets, and the possibility that the business combination search fails.
- Disclosure controls were deemed ineffective due to a material weakness in earnings-per-share presentation. Management described remediation plans but gave no assurance they would succeed.
- The company cited potential effects from COVID-19 and the Russia-Ukraine conflict, whose impacts were not determinable. It reported no legal proceedings and no material risk-factor changes from prior filings.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Chavant Capital Acquisition Corp., not Mobix Labs, Inc.
- Check subsequent filings for the business-combination outcome, extension deadline, redemptions, and remaining trust funds.
- Reconcile sponsor loan notes with amounts actually drawn and assess funding available outside the trust.
- Review remediation of the earnings-per-share control weakness and any later control assessments.
- Assess warrant terms, potential dilution, and the possibility that warrants become worthless if no combination is completed.